Compass Therapeutics Inc (CMPX) Stock Price, Quote & News

Company Profile

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in the development of antibody-based therapeutics for the treatment of various human diseases in the United States. The company's lead product candidates include tovecimig, a bispecific antibody that blocks Delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A) signaling pathways, which are critical to angiogenesis and tumor vascularization; CTX-471, an IgG4 monoclonal antibody...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 500 8099

Website: www.compasstherapeutics.com

Address:

80 Guest Street, Suite 601, Boston, United States

Plain360 Jun. 30 at 5:33 PM

$CMPX What are you waiting for? Get in now, this now has the interest of RFK Jr. Secretary of Health and Human Services.

0 · Reply

Plain360 Jun. 29 at 7:45 PM

$CMPX this will begin moving past 3.00 by Thursday

0 · Reply

MajorStockTradingLLC Jun. 28 at 8:16 PM

$CMPX This big boy is primed to see the stars, but it needs fuel to get there, buy whatever you can afford on Monday and make some cash. Even it is only 10 shares you could earn an extra few bucks. Follow me and trade with me because it is free. #America #Freedom

0 · Reply

MajorStockTradingLLC Jun. 27 at 10:28 AM

$GVH $OTRK $BULL $CMPX $OST $INMB are going to get you that new car, secret sleepers $DDD $PHGE

0 · Reply

MajorStockTradingLLC Jun. 26 at 8:17 PM

$CMPX this has a huuuuge federal contract and when MAHA gets on it, it will skyrocket.

0 · Reply

MajorStockTradingLLC Jun. 26 at 7:38 PM

$CMPX This is headed up get in now and get RICH

0 · Reply

Johndoe456 Jun. 23 at 11:02 PM

$CMPX Why this doesn’t have more watchers 🤔👀

0 · Reply

KING_OF_BIO Jun. 18 at 7:23 PM

$CMPX

0 · Reply

Greenpa Jun. 10 at 8:29 AM

$CMPX PD1/vegF is a hot space after Pfizer deal. Guess what company has a preclinical high potency bispecific for which it is seeking IND status later this year. CEO discussed inbound interest at some length in recent Jeffries conference. The webcast is available on CMPX website. Worth a listen before you consider selling as you should know what you own. There “may” be gold in them hills.

0 · Reply

ASarinana Jun. 9 at 5:06 PM

$CMPX only 571 watchers we need more people to jump in to run this up but im ok with the small increments. Slowly but surely

0 · Reply

Compass Therapeutics to Participate in the Jefferies Global Healthcare Conference

May 12, 2025, 9:51 PM EDT - 7 weeks ago

Compass Therapeutics: A Big Positive Signal For Tovecimig In Biliary Tract Cancers

May 8, 2025, 8:00 AM EDT - 7 weeks ago

Compass Therapeutics Reports 2025 First Quarter Financial Results and Provides Corporate Update

May 6, 2025, 8:00 AM EDT - 2 months ago

Compass Therapeutics to Participate in Upcoming May Investor Events

$Compass Therapeutics Presents Data on Enhanced Efficacy of CTX-471 in Combination with Tovecimig in Checkpoint-Refractory Models at the American Association for Cancer Research (AACR) Annual Meeting$

Apr 28, 2025, 8:00 AM EDT - 2 months ago

Compass Therapeutics Presents Data on Enhanced Efficacy of CTX-471 in Combination with Tovecimig in Checkpoint-Refractory Models at the American Association for Cancer Research (AACR) Annual Meeting

Apr 21, 2025, 8:00 AM EDT - 2 months ago

Compass Therapeutics Announces First Patient Dosed in an Investigator Sponsored Trial of Tovecimig in the First-Line Setting for Patients with Biliary Tract Cancer

Apr 2, 2025, 4:05 PM EDT - 3 months ago

Compass Therapeutics to Participate in the Stifel 2025 Virtual Targeted Oncology Forum

Apr 1, 2025, 7:00 AM EDT - 3 months ago

Tovecimig (CTX-009) Meets Primary Endpoint in the Ongoing Randomized Phase 2/3 Study in Patients with Biliary Tract Cancer

Mar 31, 2025, 4:05 PM EDT - 3 months ago

Compass Therapeutics to Host Webcast Highlighting Top-Line Clinical Data from the Ongoing Randomized Phase 2/3 Study Evaluating Tovecimig in Patients with Biliary Tract Cancer

Feb 27, 2025, 8:00 AM EST - 4 months ago

Compass Therapeutics Reports 2024 Financial Results and Provides Corporate Update

Dec 10, 2024, 8:00 AM EST - 7 months ago

Compass Therapeutics Appoints Biopharmaceutical Industry Leader Barry Shin as Chief Financial Officer

Dec 9, 2024, 12:54 PM EST - 7 months ago

Compass Therapeutics: Near-Term Readout, But Beware The High Stakes In Biliary Cancer

Dec 2, 2024, 8:00 AM EST - 7 months ago

Compass Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference

Nov 13, 2024, 8:30 AM EST - 8 months ago

Compass Therapeutics to Participate in Upcoming Investor Events

Nov 12, 2024, 8:00 AM EST - 8 months ago

Compass Therapeutics Reports 2024 Third Quarter Financial Results and Provides Corporate Update

Nov 8, 2024, 10:05 AM EST - 8 months ago

Compass Therapeutics Presents Novel Biomarker Data Related to CTX-471 Clinical Activity at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting

Oct 4, 2024, 10:31 AM EDT - 9 months ago

Compass Therapeutics Announces Upcoming Poster Presentation at the 39th Society for Immunotherapy of Cancer Annual Meeting

Aug 7, 2024, 8:00 AM EDT - 11 months ago

Compass Therapeutics to Participate in the Wedbush PacGrow Healthcare Conference

Jun 20, 2024, 3:14 AM EDT - 1 year ago

Compass Therapeutics: Pointing Right At Some Tough Cancers

May 28, 2024, 4:10 PM EDT - 1 year ago

Compass Therapeutics Announces CEO Transition

May 23, 2024, 5:05 PM EDT - 1 year ago

Compass Therapeutics to Present Phase 1 Data for CTX-471, A Novel CD137 Agonist Antibody, Demonstrating Anti-Tumor Activity in Patients Who Have Progressed on Approved PD-1 or PD-L1 Inhibitors at the American Society of Clinical Oncology (ASCO) Annual Mee

May 14, 2024, 8:00 AM EDT - 1 year ago

Compass Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference

May 13, 2024, 8:00 AM EDT - 1 year ago

Compass Therapeutics Reports 2024 First Quarter Financial Results and Provides Corporate Update

Apr 12, 2024, 8:00 AM EDT - 1 year ago

Compass Therapeutics Announces Poster Presentations at the Cholangiocarcinoma Foundation 2024 Annual Conference

Apr 10, 2024, 8:00 AM EDT - 1 year ago

Compass Therapeutics to Participate in the Stifel Targeted Oncology Days

Apr 9, 2024, 12:00 PM EDT - 1 year ago

Compass Therapeutics Presents Data Demonstrating Elimination of MHC Class I Negative Tumors in In Vivo Models at the 2024 American Association for Cancer Research (AACR) Annual Meeting

Mar 21, 2024, 9:00 AM EDT - 1 year ago

Compass Therapeutics Reports 2023 Financial Results and Provides Corporate Update

Feb 29, 2024, 8:00 AM EST - 1 year ago

Compass Therapeutics to Participate in the Leerink Partners Global Biopharma Conference

Jan 5, 2024, 8:00 AM EST - 1 year ago

Compass Therapeutics Provides Corporate Update

Nov 9, 2023, 7:30 AM EST - 1 year ago

Compass Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Aug 3, 2023, 8:00 AM EDT - 2 years ago

Compass Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Jun 22, 2023, 4:05 PM EDT - 2 years ago

Compass Therapeutics to be Added to the Russell 2000® and Russell 3000® Indexes

May 4, 2023, 8:30 AM EDT - 2 years ago

Compass Therapeutics Reports First Quarter Financial Results and Provides Corporate Update

Apr 19, 2023, 8:30 AM EDT - 2 years ago

Compass Therapeutics to Participate in the Stifel 2023 Virtual Targeted Oncology Days

Mar 28, 2023, 8:30 AM EDT - 2 years ago

Compass Therapeutics to Participate in the Cantor Fitzgerald Future of Oncology Symposium

Mar 15, 2023, 8:30 AM EDT - 2 years ago

Compass Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

Feb 2, 2023, 8:30 AM EST - 2 years ago

Compass Therapeutics to Participate in the SVB Securities Global Biopharma Conference

Jan 19, 2023, 5:00 PM EST - 2 years ago

Compass Therapeutics Announces that the Phase 2 Data of CTX-009 in Combination with Paclitaxel in Patients with Biliary Tract Cancers (BTC) will be Presented at the ASCO GI Cancers Symposium on January 20, 2023

Jan 6, 2023, 8:30 AM EST - 2 years ago

Compass Therapeutics Announces First Patient Dosed in the Phase 2 U.S. Study of CTX-009 in Patients with Metastatic Colorectal Cancer

Dec 15, 2022, 8:30 AM EST - 2 years ago

Compass Therapeutics Announces Presentation of Updated Results from the Ongoing Phase 2 study of CTX-009 in Biliary Tract Cancer (BTC) at the 2023 ASCO GI Cancers Symposium January 19-21

Dec 1, 2022, 8:30 AM EST - 2 years ago

Compass Therapeutics Announces First Patient Dosed in the Phase 1b CTX-471 Combination Trial with KEYTRUDA® (pembrolizumab)

Nov 22, 2022, 8:00 AM EST - 2 years ago

Compass Therapeutics to Present at the Piper Sandler 34th Annual Healthcare Conference

Nov 9, 2022, 9:00 AM EST - 2 years ago

Compass Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Nov 8, 2022, 8:00 AM EST - 2 years ago

Compass Therapeutics to Present at Upcoming Investment Conferences

Nov 2, 2022, 9:06 AM EDT - 2 years ago

Compass Therapeutics Announces $80 Million Private Placement

Sep 9, 2022, 8:00 AM EDT - 3 years ago

Compass Therapeutics to Present at the 24th Annual H.C. Wainwright Global Investment Conference

Aug 1, 2022, 8:00 AM EDT - 3 years ago

Compass Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update

May 23, 2022, 8:00 AM EDT - 3 years ago

Compass Therapeutics to Present at the 2022 H.C. Wainwright Annual Global Investment Conference

May 9, 2022, 8:00 AM EDT - 3 years ago

Compass Therapeutics Reports First Quarter 2022 Financial Results and Highlights Recent Company Progress

May 3, 2022, 4:01 PM EDT - 3 years ago

Compass Therapeutics to Host Conference Call Highlighting Clinical Data from CTX-009

Plain360 Jun. 30 at 5:33 PM

$CMPX What are you waiting for? Get in now, this now has the interest of RFK Jr. Secretary of Health and Human Services.

0 · Reply

Plain360 Jun. 29 at 7:45 PM

$CMPX this will begin moving past 3.00 by Thursday

0 · Reply

MajorStockTradingLLC Jun. 28 at 8:16 PM

0 · Reply

MajorStockTradingLLC Jun. 27 at 10:28 AM

$GVH $OTRK $BULL $CMPX $OST $INMB are going to get you that new car, secret sleepers $DDD $PHGE

0 · Reply

MajorStockTradingLLC Jun. 26 at 8:17 PM

$CMPX this has a huuuuge federal contract and when MAHA gets on it, it will skyrocket.

0 · Reply

MajorStockTradingLLC Jun. 26 at 7:38 PM

$CMPX This is headed up get in now and get RICH

0 · Reply

Johndoe456 Jun. 23 at 11:02 PM

$CMPX Why this doesn’t have more watchers 🤔👀

0 · Reply

KING_OF_BIO Jun. 18 at 7:23 PM

$CMPX

0 · Reply

Greenpa Jun. 10 at 8:29 AM

0 · Reply

ASarinana Jun. 9 at 5:06 PM

$CMPX only 571 watchers we need more people to jump in to run this up but im ok with the small increments. Slowly but surely

0 · Reply

lexlut Jun. 9 at 2:55 PM

$CMPX News from ASCO?

0 · Reply

lexlut Jun. 9 at 2:27 PM

$OCGN Buy $CMPX

0 · Reply

PenkeTrading Jun. 6 at 4:02 PM

I found you an Overbought RSI (Relative Strength Index) on the daily chart of Compass Therapeutics Inc.. Is that bullish or bearish? $CMPX #Compass #RsiOverbought #NASDAQ

0 · Reply

lexlut Jun. 5 at 5:50 PM

$CMPX News oncology

0 · Reply

lexlut Jun. 5 at 5:36 PM

$CMPX $OCGN Buy

0 · Reply

Benroxx Jun. 3 at 3:03 PM

$CMPX $DJT $MSFT $NVAX He feels sorry on his old days for all the bad he has done to African people over the years

0 · Reply

redsstocktwits Jun. 3 at 2:49 PM

$CMPX I was hoping that this will not do what NVAX did to me years ago... You know i was an early investor of $NVAX supported NVAX thru its difficult time as retail investor but THE MOMENT they the future becoming bright BILL GATES comes in and DO YOU WHAT THEY DID TO RETAIL investors before Bill gates comes in. THEY DID THE REVERSE SPLIT basically screwing us up EARLY INVESTORS of NVAX... THAT IS WHY Its a shame THAT BILL GATES SAYS... OH YEAH HE DON'T LIKE TO BE REVEMBER AS DYING SUPER RICH so he is donating the bulk of his fortune to Africa. WELL ALL I CAN SAY IS THIS. MR. GATES you amass that wealth BY screwing up AMERICAN and capitalist investors of the world like us retail investors, you basically Keep on upgrading windows, then remove support for old version so that American consumer force to upgrade and give $MSFT billions of profit. WHAT A HYPOCRITE YOU ARE. You are one of the reason why some are going socialist. CC $DJT https://www.bbc.com/news/articles/cn4qg5gzgzxo

2 · Reply

KING_OF_BIO May. 30 at 12:44 PM

$CMPX Did I hear debt free? And CEO just purchased 10k shares?

0 · Reply

CEOBuysDisclosures May. 27 at 9:30 PM

$CMPX CEO purchased 10,000 shares at $2.11 for a total of $21,100. Schuetz Thomas J. now owns 6,480,825 shares. https://ceo-buys.com

0 · Reply

ASarinana May. 21 at 7:06 AM

$CMPX NO debt this one keeps getting better.

0 · Reply

lexlut May. 20 at 7:19 PM

$OCGN $CMPX 💸💸💸💸💸💸💸💸💸💸💸💸💸💸💸

0 · Reply

Groggok May. 20 at 2:21 AM

$CMPX $PFE opening up wallet in oncology https://longportapp.com/en/news/240931155

0 · Reply

Market Cap	354.01M
Revenue (ttm)	850,000.00
Net Income (ttm)	-49.38M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-5,809.41%
Debt to Equity Ratio	0.00

Volume	445,900
Avg Vol	851,256
Day's Range	N/A - N/A
Shares Out	138.28M
Stochastic %K	73%
Beta	1.41
Analysts	Strong Sell
Price Target	$13.22